Merck's Keytruda Drives 156th Ranked Trading Volume Amid 30 Percent Decline

On July 24, 2025, Merck & Co., Inc. (MRK) saw a trading volume of $673 million, marking a 30.26% decrease from the previous day. The stock ranked 156th in terms of trading volume for the day. MRK's stock price rose by 0.15%, marking its third consecutive day of gains, with a total increase of 6.05% over the past three days.

Merck's primary strength lies in oncology, driven by its blockbuster PD-L1 inhibitor, Keytruda. This drug has been instrumental in fueling robust growth across various cancer treatments. Keytruda's success is expected to continue supporting Merck's top line ahead of its Q2 earnings report.

Analysts project that Merck's 'Sales- Oncology- Keytruda - International' will reach $3.16 billion, indicating a year-over-year change of +5.9%. This projection underscores the significant contribution of Keytruda to Merck's revenue growth.

Merck recently received Canadian approval for Keytruda in combination with other treatments for cervical cancer. This approval expands the drug's indications and further solidifies its position as a key player in the oncology market.